This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in
Alaska natives with alcohol dependence. The study will also examine whether a combination
of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used
alone. Alaska Native individuals will be recruited into a 16 week outpatient study.
- Alaska Native having biological Alaska Native ancestry.
- Meets criteria for alcohol dependence.
- Prior to entering the study must be abstinent between 3 and 14 days and have a
- Stable residence to ensure that subjects can be located during the study.
- Currently meets criteria for abuse or dependence on substances other than alcohol or
- Current use of disulfiram.
- Psychotic or otherwise severely psychiatrically disabled.
- Use of other psychotropic medications including antidepressants and anxiolytics.
- Medical conditions that would not permit the use of sertraline or naltrexone, such as
a history of unstable or severe hepatic, cardiovascular, metabolic, endocrine,
gastrointestinal or kidney disease.
- Hepatocellular disease or elevated bilirubin levels.
- Females who are pregnant, nursing, or not using a reliable method of birth control.
- Probation or parole requirements that might interfere with participation in the
- Involvement in alcohol treatment other than provided by the study or AA.
- Use of monoamine oxidase inhibitors in the past month.
- Current use of Type 1C antiarrhythmics propafenone and flecainide.